Rana McKay, Associate Professor of Medicine at University of California San Diego, shared a post on X:
“Treatment decisions for frontline RCC getting more complicated with long term data from key landmark studies. We need better (negative selection) biomarkers to choose between IO-IO and IO-VEGF.”
Full Article on ASCO Daily News.